Price$6.02-0.27 (-4.29%)
01:30 PM07:45 PM
News · 26 weeks36+50%
2026-04-262026-10-18
Mix2290d
- SEC Filings11(50%)
- Other7(32%)
- Earnings2(9%)
- Analyst1(5%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Profound Medical Corp.8-K - Profound Medical Corp. (0001628808) (Filer)
- PRTULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion OpportunityTORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced that five abstracts presented at the 15th Interventional MRI ("iMRI") Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO® system. Collectively, the presentations underscore three important dimensions of TULSA’s progress: Real-world validation: Findings from the CARE Registry and single-center experiences at Mayo Clinic in Florida and Rochester provide complementary evidence of TULSA
- SECSEC Form 8-K filed by Profound Medical Corp.8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CareCollaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, is pleased to announce entering into a co-education
- SECSEC Form 8-K filed by Profound Medical Corp.8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Reports Strong Preliminary Third Quarter 2026 RevenueTORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary unaudited revenues for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. Based on these preliminary results, the Company expects to report record-breaking quarterly revenue that is above current Wall Street expectations. Preliminary Financial Highlights: Total Revenue: Expected to be in the range of $9.8 million to $10.0 million.Year-over-Ye
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth ConferenceTORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets "BIG10" Conference on September 10, 2026 in New York City. The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available. About Profound Medical Corp. Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MR
- SECProfound Medical Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as PresidentTORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately. Mr. Fabian succeeds Mathieu Burtnyk, PhD, who has shifted to the newly created position of Chief Technology Officer. Mr. Fabian has an accomplished history of sales, marketing, operations, general and executive management success within the global healthcare industry, specifically in the medical imaging and medical device spaces. In a career spanning more than 2
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’TORONTO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced the introduction of its latest Treatment Delivery Consol ("TDC") software. The new TDC software, which is being deployed across Profound’s TULSA-PRO® installed base, further builds upon previously implemented TULSA-AI® modules focused on increasing procedural efficiency and physician experience, while reducing planning complexity. It brings two new focuses of features that are designed to even further increase TULSA Procedure™ efficiency
- SECProfound Medical Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Announces Management ChangeTORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company’s Chief Financial Officer. "I would like to thank Rashed for his years of service and the contributions he has made to the Company, and I am pleased that he will be staying on a short-term consulting contract to help en
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care JourneyTORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced the launch of Let's Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every stage of the prostate care journey. The new patient advocacy initiative, led by Leonard Wheeler, Profound’s Global Patient Ambassador, former NFL player, prostate cancer survivor, and men's health advocate, brings together patients, survivors, care partners, healthcare professionals, an
- SECSEC Form 10-Q filed by Profound Medical Corp.10-Q - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Reports Second Quarter 2026 Financial Results– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and reimbursement momentum continues – – Company reiterates full-year 2026 revenue guidance – – Announces first employer owned health plans to list the TULSA Procedure™ as a covered service – TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced financial results for the second
- ANALYSTProfound Medical upgraded by Raymond James with a new price targetRaymond James upgraded Profound Medical from Outperform to Strong Buy and set a new price target of $11.00
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRRobotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN TrialTORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced new data from the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure™ with robotic radical prostatectomy ("robotic RP") in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. At 1 month following the TULSA Procedure, there was no median change in penile length, compared with a median 0.65 cm reduction in penile length after robotic RP. The new penile length re
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to FollowTORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2026 Results Conference Call Details: Date: Thursday, August 6, 2026 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI1680e67d2b6f4f81b268df3183400d
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
PROF FAQ
6 questionsWhat does Profound Medical Corp. do?
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive...Where does PROF stock trade?
Profound Medical Corp. (PROF) is listed on NASDAQ.What sector and industry is PROF in?
Profound Medical Corp. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about PROF?
Profound Medical Corp. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1100.00 price target on 2026-07-27. Recent price targets range from $1000.00 to $2300.00.What companies are similar to PROF?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PROF side-by-side with any of them on Quantisnow.How can I track PROF on Quantisnow?
Quantisnow aggregates Profound Medical Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PROF to receive live email and push alerts on every new disclosure.